

2026 Independent Medical Education Request for Proposals

Issue Date: July 22, 2026

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposals (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

Instructions

Eligibility Criteria	• U.S. based education provider • Registered account in gFRS • Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	• Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 8 weeks to complete a full grant proposal through funding.gene.com . When submitting the application, please be sure to: • Select the Therapeutic Area (Oncology), and Disease State (Non-Small Cell Lung Cancer) • Include “RFP July 2026 [Insert Program Title]” in the program title of the grant	September 16, 2026
Step 2	Grant decisions will be made by Genentech and decision notifications will be issued to the accredited educational provider through gFRS.	September 2026 through December 2026

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or improved patient outcomes as a result of the educational activity.
3. Summarize (through written analysis) the provider’s understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available RFP Focus Area:

Focus	Opportunity
Therapeutic Area: Oncology Disease Areas: Non-Small Cell Lung Cancer Primary Learning Audiences: Community Oncologists Community Cancer Teams Support Available: Up to \$225,000	Lung cancer is the leading cause of cancer death in the world (Sung et al. 2021). Standard first-line treatment for advanced or metastatic NSCLC (including <i>KRAS G12C</i> +) includes platinum-based chemotherapy, immunotherapy, or a combination of chemotherapy and immunotherapy. NSCLC that has been treated with standard-of-care chemotherapy and/or immunotherapy in the advanced or metastatic setting has a poor prognosis. Genomic and molecular screening for predictive biomarkers has become increasingly important for NSCLC and has transformed patient outcomes (Restrepo et al. 2023). <i>KRAS G12C</i> + NSCLC represents a genomically distinct subset of the disease for which targeted therapies have recently become available. Patients with <i>KRAS G12C</i> + NSCLC initially (e.g., first and/or second line) receive similar treatments as patients who have <i>KRAS G12C</i>-negative NSCLC in the absence of other actionable driver alterations. For patients with <i>KRAS G12C</i> + NSCLC who have received standard first-line metastatic NSCLC treatments, several oral therapies specifically targeting the mutation have been developed and are available in many countries. The rapid advancements from first-generation inhibitors to next-generation <i>KRAS G12C</i>-targeting agents has created an overwhelming volume of clinical evidence. Community oncologists, who often operate as generalists treating diverse tumor types, face challenges in maintaining up-to-date knowledge regarding these advancements. To optimize patient outcomes, Genentech is seeking proposals for programs that address the educational needs of community oncologists and community cancer multidisciplinary teams concerning new treatment options in <i>KRAS G12C</i> + NSCLC. References: - Restrepo, J. C., Dueñas, D., Corredor, Z., & Liscano, Y. (2023). Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment. <i>Cancers</i>, 15(13), 3474. https://doi.org/10.3390/cancers15133474 - Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <i>CA: a cancer journal for clinicians</i>, 71(3), 209–249. https://doi.org/10.3322/caac.21660